公开(公告)号：US20240252750A1

公开(公告)日：2024-08-01

申请号：US18629118

申请日：2024-04-08

Applicant: INSULET CORPORATION

Inventor： Ashutosh ZADE ,  Joon Bok LEE ,  Yibin ZHENG ,  Eric DUHAMEL

IPC: A61M5/172 ,  A61M5/14 ,  A61M5/142 ,  G16H40/63

CPC classification number: A61M5/1723 ,  A61M5/1413 ,  A61M5/14248 ,  G16H40/63 ,  A61M2005/1401 ,  A61M2005/14208 ,  A61M2005/14292 ,  A61M2005/1726 ,  A61M2205/10 ,  A61M2205/3303 ,  A61M2205/3327 ,  A61M2205/3386 ,  A61M2205/3553 ,  A61M2205/3569 ,  A61M2205/505 ,  A61M2205/584 ,  A61M2230/201

Abstract: Disclosed are processes and techniques implementable by a drug delivery system to maintain optimal drug delivery for a patient according to a treatment plan. The disclosed techniques enable a new drug delivery device that is exchanged for a previous drug delivery device to operate using analyte-based drug delivery control immediately during initialization instead of having to wait for a warm-up period. For example, a drug delivery device may include a processor and a memory storing instructions that, when executed by the processor, operate the drug delivery device to receive a present analyte measurement value from an analyte sensor during an initialization of the drug delivery device, receive backfill values measured by the analyte sensor prior to the initialization, calculate a dosage of a drug using the present analyte measurement value and the backfill values, and deliver the dosage of the drug. Other embodiments are described.

公开(公告)号：US20240165328A1

公开(公告)日：2024-05-23

申请号：US18422986

申请日：2024-01-25

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Trang LY

IPC: A61M5/172 ,  A61B5/00 ,  A61B5/145 ,  A61M5/142 ,  G06Q30/0283 ,  G16H20/17

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61B5/4839 ,  A61M5/142 ,  G06Q30/0283 ,  G16H20/17 ,  A61M2005/14208 ,  A61M2205/52 ,  A61M2230/201

Abstract: The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).

公开(公告)号：US20240100253A1

公开(公告)日：2024-03-28

申请号：US18466211

申请日：2023-09-13

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2202/0486 ,  A61M2230/04 ,  A61M2230/40

Abstract: Disclosed are techniques, devices and systems that provide adjustments to parameter settings of an insulin delivery algorithm based on inputs from a number of generic sensor devices. A majority of the generic sensor devices provide sensor readings that are unused as inputs to a drug deliver algorithm. The generic sensor devices may be operable to detect characteristics, such as changes in a state of a user. A processor may evaluate a sensor reading provided by a particular sensor with respect to a sensor baseline reading for the particular sensor. Using the result of the evaluation, the processor may calculate an adjustment to a parameter setting or settings of a medication delivery algorithm. A dosage of medication may be modified based on the adjustment of the parameter setting or settings.

公开(公告)号：US20240079111A1

公开(公告)日：2024-03-07

申请号：US18454323

申请日：2023-08-23

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  John D’ARCO ,  Jason O'CONNOR

IPC: G16H20/17 ,  A61M5/142

CPC classification number: G16H20/17 ,  A61M5/142 ,  A61M2005/14208

Abstract: Disclosed herein is a method, implemented in an automatic drug delivery system, for determining insulin resistance of a user and adjusting parameters of the medication delivery algorithm of the automatic drug delivery system based on the determined insulin resistance. A self-guided test is administered similar to the Kraft test which determines if the quantity of insulin delivered during a post-prandial period after ingestion of a quantity of fast-acting carbohydrates is sufficient to lower the user's blood glucose level to a baseline level.

公开(公告)号：US20240075214A1

公开(公告)日：2024-03-07

申请号：US18450238

申请日：2023-08-15

Applicant: INSULET CORPORATION

Inventor： Ashutosh ZADE ,  Joon Bok LEE ,  Yibin ZHENG ,  Rangarajan NARAYANASWAMI ,  Jason O’CONNOR

IPC: A61M5/315 ,  G16H20/17

CPC classification number: A61M5/31566 ,  G16H20/17

Abstract: Safety and accuracy measures may be provided in a medicament delivery device. The medicament delivery device may be able to identify the inadvertent delivery of duplicate medicament boluses by a user. The exemplary embodiments may set limits for maximum allowable medicament bolus doses and maximum cumulative bolus doses over an interval. The exemplary embodiments may provide automatic meal detection and may use detection of meals in determining whether a user-requested medicament bolus dose should be adjusted or rejected. The exemplary embodiments may facilitate delivery of partial boluses and the delivery of remainders of the boluses contingent on acceptable glucose level trends of the user. The exemplary embodiments may resolve potential conflicts among multiple medicament delivery devices via a broker or by providing a single actor, such as a medicament delivery controller, that has sole control of dosing and delivery of medicament boluses.

公开(公告)号：US20240066224A1

公开(公告)日：2024-02-29

申请号：US18451530

申请日：2023-08-17

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Jason O’CONNOR

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61M2202/0486 ,  A61M2205/50

Abstract: Exemplary embodiments may apply a transform or filter to analyte level values of the users to make the analyte level values conform with a normal distribution that is symmetric relative to the mean. The transformed or filtered analyte level values may be used by the control system of a medicament delivery device in determining medicament delivery doses. In some embodiments, the medicament is insulin, and the analyte level is a glucose level of a user. In such instances, a logarithmic filter or transform may be applied to the glucose level readings of the user.

公开(公告)号：US20240058534A1

公开(公告)日：2024-02-22

申请号：US18499515

申请日：2023-11-01

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2005/14208 ,  A61M2205/3303 ,  A61M2205/3569 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/201

Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide techniques to implement functionality to receive blood glucose measurements over a period of time. An average of missing blood glucose measurement values may be maintained over a predetermined time period. A count of a number of missing blood glucose measurement values over a period of time may be established. A controller may calculate a divergence of the number of missing blood glucose measurement values over the period of time from the average of missing blood glucose measurements over the predetermined time period. Based on a value of the divergence, a determination that a safety constraint for delivery of insulin is to be reduced. The safety constraint may be reduced by a predetermined percentage. An instruction to deliver an insulin dosage may be generated according to the reduced safety constraint may be forwarded to a wearable drug delivery device.

公开(公告)号：US20230285670A1

公开(公告)日：2023-09-14

申请号：US18119059

申请日：2023-03-08

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Ashutosh ZADE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Mengdi LI

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2202/0486 ,  A61M2205/50 ,  A61M2205/52

Abstract: The exemplary embodiments may provide adaptivity in the basal portion value. The exemplary embodiments may also provide adaptivity of the total daily medicament (TDM) delivery amount. The adaptivity provided by the exemplary embodiments helps to customize medicament delivery to the needs of the user of a medicament delivery device. The exemplary embodiments may adapt the basal ratio for the user based on historical medicament delivery data for the user. In addition, the exemplary embodiments may update the basal ratio based upon more recent trends that diverge from the historical medicament delivery data. The degree of adaptivity provided by the exemplary embodiments may be bound to not exceed an upper threshold and/or a lower threshold. The degree of adaptivity may be modulated by controlling the rate of adaptivity too small increments each time the basal ratio is updated.

公开(公告)号：US20230277766A1

公开(公告)日：2023-09-07

申请号：US18316703

申请日：2023-05-12

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142 ,  A61K38/28 ,  G16H20/17 ,  G16H40/67 ,  G05D7/06 ,  G05B15/02

CPC classification number: A61M5/172 ,  A61M5/14248 ,  A61K38/28 ,  G16H20/17 ,  G16H40/67 ,  G05D7/0623 ,  G05D7/0676 ,  G05B15/02 ,  A61M2205/18 ,  A61M2205/52 ,  A61M2205/3331 ,  A61M2205/3584

Abstract: Disclosed are techniques to establish a modified pump rate that mitigates the effects of a pump occlusion and enables a recommended dosage of insulin to be output by a pump mechanism over the course of a control cycle. In an example, the pump rate may be reduced by adding a calculated time interval between application of actuation commands to extend the amount of time over which insulin may be output by the pump mechanism.

公开(公告)号：US20230233764A1

公开(公告)日：2023-07-27

申请号：US18157400

申请日：2023-01-20

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG ,  Graeme NELSON

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2205/52 ,  A61M2205/502 ,  A61M2230/201

Abstract: Disclosed are a computing apparatus, a computer-readable medium and a method that enable a user to use subjective inputs to alter settings of a wearable automatic drug delivery system. A user input device is presented on a graphical user interface that enables input of a subjective insulin need parameter. In response to receiving the input, the processor may modify a subjective coefficient value. A specific factor useable by an automatic insulin delivery algorithm is set based on the subjective coefficient value. Physiological condition data related to the user and the set specific factor may be used to determine a dosage of insulin to be delivered to the user based on the collected physiological condition data of the user. The processor may cause the determined dosage of insulin to be delivered to the user based on an output of the automatic insulin delivery algorithm.